Underpowered PANTS: a response to the conclusions of “extended analysis identifies drug-specific association of two distinct HLA class II haplotypes for development …
In our original study, we decided a priori to maximize power to detect genetic variants
associated with immunogenicity to anti-TNFs by including patients treated with either drug in
the primary analysis. We reported a significant association between the allele group HLA-
DQA1∗ 05 and time to development of antibodies to anti-TNF drugs (hazard ratio [HR], 1.90;
95% confidence interval [CI], 1.60–2.25; P= 5.88× 10–13). We did not detect significant
heterogeneity of an effect between patients treated with adalimumab or infliximab, or for …
associated with immunogenicity to anti-TNFs by including patients treated with either drug in
the primary analysis. We reported a significant association between the allele group HLA-
DQA1∗ 05 and time to development of antibodies to anti-TNF drugs (hazard ratio [HR], 1.90;
95% confidence interval [CI], 1.60–2.25; P= 5.88× 10–13). We did not detect significant
heterogeneity of an effect between patients treated with adalimumab or infliximab, or for …
